Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

Phase 2 Study to Explore the Efficacy of Novel Proteasome Inhibitor in

Patients with Relapsed and Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, Calif. and NORWALK, Conn., Aug. 15 /PRNewswire/ -- The Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today announced the enrollment of the first patient in a multi-center Phase 2 clinical trial to study Proteolix's potent and selective proteasome inhibitor, carfilzomib (PR-171), in patients with relapsed and refractory multiple myeloma. Ten MMRC Member Institutions will participate in the study, under the MMRC leadership of Melissa Alsina, MD, H. Lee Moffitt Cancer Center & Research Institute. The nine additional sites are the City of Hope, Emory University, Cancer Center at Hackensack University Medical Center, Mayo Clinic, Princess Margaret/University Health Network, Saint Vincent's Comprehensive Cancer Center, University of Michigan, and Washington University.

The MMRC is the only research model of its kind that brings together 13 leading academic institutions to accelerate the development of novel and combination treatments for multiple myeloma, an incurable cancer of the plasma cell.

"Proteasome inhibitors are an important class of drugs for the treatment of multiple myeloma and we are proud to work with Proteolix to advance the clinical development of carfilzomib," said Kathy Giusti, Founder and Chief Executive Officer of the MMRC. "This trial and the others the MMRC are facilitating underscore our commitment to bring better, more effective treatments to myeloma patients as quickly as possible."

The trial will evaluate the overall response rate (ORR) for two cycles of carfilzomib in patients with multiple myeloma who have previously received specific FDA-approved therapies, have relapsed after two or more of such therapies, and are refractory to the most recently received therapy. Secondary objectives of this study include safety and tolerability, clinica
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  Luoxis Diagnostics, ... MKT: AMPE), today announced that its academic collaborators ... and research potential for its novel RedoxSYS Diagnostic ... (ORP) in the body in response to injury ... of ORP as a clinical marker will be ...
(Date:10/20/2014)... , Oct. 20, 2014 Valeritas, Inc., ... designed for patients with Type 2 diabetes, announced today ... Chain Excellence Award. The award was presented October 16 ... Columbus, Ohio . ... judged across a variety of metrics specifically targeted at ...
(Date:10/20/2014)... Oct. 20, 2014  AnaptysBio, Inc., a leader ... today announced the appointment of Marco Londei ... will lead the preclinical and clinical development of ... are pleased to welcome Dr. Londei to AnaptysBio,s ... President and Chief Executive Officer of AnaptysBio. "Dr. ...
Breaking Medicine Technology:Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... , , ROCKVILLE, Md. , ... ) announced today that the company has decided to discontinue ... ROVI Pharmaceuticals ( Madrid : ROVI) to develop Novavax,s virus-like-particle ... .  This decision is due to the companies, inability to ...
... , SALT LAKE CITY , Feb. ... Corporation ("WorldHeart" or "Company"), a developer of mechanical circulatory systems, ... Company  received a NASDAQ Staff Deficiency Letter indicating that the ... Rule requires the Company to have at least three independent ...
Cached Medicine Technology:Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 2Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 3Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 4NASDAQ Stock Market Confirms WorldHeart's Compliance With NASDAQ Listing Rule 5605 2
(Date:10/22/2014)... 2014 On Saturday, October 25, 2014, the ... family health and fitness fair ¡Vive tu vida! Get Up! ... good nutrition for better health and wellness for people of ... and open to the public, will be held at Dean ... am to 1:00 pm. , “¡Vive tu Vida! Get ...
(Date:10/22/2014)... 22, 2014 Medical Solutions ... is happy to announce that our co-founder and ... Industry Analysts’ Staffing 100 for 2014. Anderson was ... most influential people in the staffing industry,” in ... the 13th-largest healthcare staffing company in the U.S., ...
(Date:10/22/2014)... 2014 For Dr. Iris Hunter, a job ... an extension of her life’s mission. Her extensive experience in ... owner of FirstLight HomeCare, make it clear that Hunter’s mission ... that my work makes a difference in the lives of ... so after much research, I felt ready to start on ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
(Date:10/22/2014)... Va. (PRWEB) October 22, 2014 ... Innovation , which is dedicated to distribute health ... of healthcare delivery worldwide announced the development of ... which patients expect when receiving healthcare. These are ... for patient-centered care: “providing care that is respectful ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2
... ... "CSPA has not had an opportunity for a detailed review ... cannot,make any definitive comment on this specific study, we can ... correlation of,various data. This process does not necessarily demonstrate a ...
... Pa., Oct. 12 Helping its,employees to live a ... Recently, the American Heart Association (AHA) recognized,SAE for those ... Friendly Company, an honor,presented to only a handful of ... What does it mean? In short, it means that ...
... Parametric Release(TM) Instrument Processor, TUCSON, Ariz., Oct. ... of The Manzi Mach 1 Cleaner-Processor, the only,Parametric ... a,fully integrated cleaning, sterilizing and rinsing system that ... This system is designed for,use by hospitals, medical ...
... October 12, 2007 -- Excerpta Medica, an Elsevier ... six decades, has merged with corporate sibling Elsevier ... agency with more than a decades experience creating ... brands. Excerpta Medica will now be able ...
... GNC -- along with thousands of,herb-loving individuals, ... National Herb Day 2007 tomorrow, Oct. 13. The ... of October by giving,customers free 28-ct Mega Men(R) ... or more on herbs. National Herb Day ...
... only real-time PCR test for HIV, INDIANAPOLIS, Oct. ... its 1,700 hospital members access in,August to the Roche ... test for HIV offered to its members. Premier ... and COBAS(R) TaqMan(R) Analyzer to its existing three-year,molecular contract ...
Cached Medicine News:Health News:Consumer Specialty Products Association Responds to European Study Investigating Spray Products and Asthma 2Health News:FDA Grants Clearance to Langford IC Systems, Inc. 2Health News:FDA Grants Clearance to Langford IC Systems, Inc. 3Health News:GNC Honors Herb Day Tomorrow (and All Month Long) 2Health News:Nation's Largest Healthcare Alliance Adds Roche HIV-1 Test to Existing Contract 2Health News:Nation's Largest Healthcare Alliance Adds Roche HIV-1 Test to Existing Contract 3
9.5" overall length, 4.5" handle....
15" overall length, 9" handle....
...
EDM Ventricular Drainage Kit, with Drip Chamber with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in ...
Medicine Products: